Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
- Conditions
- Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple SclerosisNon-Active SPMSAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesDemyelinating DiseasesImmune System Diseases
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 34
- Registration Number
- NCT06677710
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
🇺🇸Stanford University, Stanford, California, United States
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT06675955
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 5
- Registration Number
- NCT06495593
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
WOE of Anti-CD20 Therapies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06121349
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 296
- Registration Number
- NCT05296161
- Locations
- 🇳🇱
Amsterdam UMC, location VU, Amsterdam, Noord-Holland, Netherlands
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 123
- Registration Number
- NCT05285891
- Locations
- 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1300
- Registration Number
- NCT05269004
- Locations
- 🇦🇺
St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇷🇺Sverdlovsk Regional Clinical Hospital 1, Yekaterinburg, Sverdlovsk, Russian Federation
🇺🇸Northwestern University, Chicago, Illinois, United States
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 72
- Registration Number
- NCT05210621
- Locations
- 🇫🇷
Amiens University Hospital, Amiens, France
🇫🇷Bayonne Hospital, Bayonne, France
🇫🇷Caen University Hospital, Caen, France
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05208840
- Locations
- 🇷🇺
City Clinical Hospital #24; Multipal Sclerosis department, Moskva, Moskovskaja Oblast, Russian Federation
🇷🇺National Center of Socially Significant Diseases, Saint-Petersburg, Sankt Petersburg, Russian Federation
Ocrelizumab Access by Socio-Economic Status
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 600
- Registration Number
- NCT05131984
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.